Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$101M in Q4 2025 → $140M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Veradermics Inc | 12.8% | Added 42% | 145,695 | $17.9M |
| X4 Pharmaceuticals Inc | 12.5% | Unchanged | 3,722,840 | $17.4M |
| Compass Pathways PLC | 8.3% | Unchanged | 819,692 | $11.6M |
| Surrozen Inc | 7.2% | Unchanged | 385,178 | $10M |
| Aclaris Therapeutics Inc | 6.9% | Added 37% | 1,832,365 | $9.69M |
| Sionna Therapeutics Inc | 6.2% | Unchanged | 197,072 | $8.67M |
| Inhibikase Therapeutics Inc | 5.6% | Added 43% | 3,821,890 | $7.76M |
| PN Pharvaris Nv | 4.9% | Unchanged | 198,772 | $6.87M |
| Karyopharm Therapeutics Inc | 4.8% | New | 685,644 | $6.7M |
| Septerna Inc | 4.7% | Unchanged | 194,544 | $6.52M |
| Inflarx Nv | 4.7% | New | 2,897,769 | $6.49M |
| CT Cyclerion Therapeutics Inc | 4.0% | New | 1,651,350 | $5.6M |
| UN Uniqure Nv | 2.6% | Trimmed 62% | 79,407 | $3.66M |
| Leonabio Inc | 2.6% | Unchanged | 393,701 | $3.62M |
| Damora Therapeutics Inc | 2.6% | Unchanged | 139,000 | $3.62M |
| Moonlake Immunotherapeutics | 2.5% | Unchanged | 175,734 | $3.42M |
| Tyra Biosciences Inc | 1.7% | Unchanged | 74,465 | $2.38M |
| Nuvectis Pharma Inc | 1.3% | New | 100,000 | $1.84M |
| Gossamer Bio Inc | 1.3% | Added 49% | 11,149,363 | $1.84M |
| Milestone Pharmaceuticals Inc | 1.2% | New | 1,269,237 | $1.7M |
| Atyr Pharma Inc | 0.8% | New | 1,788,167 | $1.07M |
| Instil Bio Inc | 0.5% | Trimmed 29% | 99,600 | $766K |
| Tscan Therapeutics Inc | 0.3% | New | 454,876 | $446K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AA Alpha Architect 1-3 Month Box ETF | Exited | −118,422 | −$13.8M | — |
| Relay Therapeutics Inc | Exited | −901,457 | −$8.97M | — |
| Karyopharm Therapeutics Inc | New | +685,644 | +$6.7M | 4.8% |
| Inflarx Nv | New | +2,897,769 | +$6.49M | 4.7% |
| UN Uniqure Nv | Trimmed | −132,295 | −$6.09M | 2.6% |
| Oruka Therapeutics Inc | Exited | −118,524 | −$5.81M | — |
| CT Cyclerion Therapeutics Inc | New | +1,651,350 | +$5.6M | 4.0% |
| Veradermics Inc | Added | +42,816 | +$5.26M | 12.8% |
| Aclaris Therapeutics Inc | Added | +494,809 | +$2.62M | 6.9% |
| Inhibikase Therapeutics Inc | Added | +1,149,282 | +$2.33M | 5.6% |
Showing the 10 largest of 20 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AA Alpha Architect 1-3 Month Box ETF | Trimmed | −112,365 | −$13.1M | 11.6% |
| Veradermics Inc | New | +102,879 | +$6.5M | 5.5% |
| Aclaris Therapeutics Inc | New | +1,337,556 | +$5.02M | 4.2% |
| Damora Therapeutics Inc | New | +139,000 | +$3.6M | 3.0% |
| Allogene Therapeutics Inc | Exited | −2,546,129 | −$3.49M | — |
| UN Uniqure Nv | New | +211,702 | +$3.46M | 2.9% |
| Gossamer Bio Inc | New | +7,471,840 | +$2.45M | 2.1% |
| Oric Pharmaceuticals Inc | Exited | −267,059 | −$2.18M | — |
| Verrica Pharmaceuticals Inc | Exited | −235,779 | −$1.96M | — |
| Inhibikase Therapeutics Inc | Added | +922,608 | +$1.55M | 3.8% |
Showing the 10 largest of 14 changes.
Loading...
